Join
Live feed
·
INSIDERFilingvia Quantisnow
Avalo Therapeutics Inc. logo

Chief Financial Officer Sullivan Christopher Ryan sold $1,450,419 worth of shares (72,725 units at $19.94) as part of a pre-agreed trading plan and exercised 71,852 shares at a strike of $9.88, decreasing direct ownership by 2% to 39,900 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AVTX (Avalo Therapeutics Inc.) and more on Quantisnow.